North China Pharmaceutical (SHA:600812), through unit Shenzhen Huayao Nanfang Pharmaceutical, received a drug registration certificate for imipenem and cilastatin sodium for injection from the Chinese drug administration, according to a Wednesday disclosure on the Shanghai bourse.
The certificate gives approval for the pharmaceutical company to produce and market the drug, which was developed to treat infections caused by susceptible bacteria.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments